Osbourne G K, Whigham K A, Howie P W, England P, Kelly A, Prentice C R
Br J Obstet Gynaecol. 1978 Sep;85(9):687-91. doi: 10.1111/j.1471-0528.1978.tb14948.x.
The effects of bromocriptine and quinestrol upon coagulation and fibrinolysis during the puerperium were studied. Quinestrol therapy was associated with increased levels of factors VII and IX and decreased antithrombin activity on the sixth postpartum day, and increased factor IX and plasminogen levels on the fourteenth postpartum day. Six weeks after delivery elevated levels of factors II and VII and of plasminogen were recorded in women given quinestrol. Bromocriptine therapy only caused an increase in the level of factor IX at six weeks after delivery. Compared to controls, patients given bromocriptine had lower prolactin and higher FSH levels during the puerperium whereas the patients given quinestrol had increased prolactin levels and a late fall in FSH levels.
研究了溴隐亭和炔雌醚对产褥期凝血和纤维蛋白溶解的影响。炔雌醚治疗使产后第6天的凝血因子Ⅶ和Ⅸ水平升高,抗凝血酶活性降低,产后第14天的凝血因子Ⅸ和纤溶酶原水平升高。分娩后6周,服用炔雌醚的女性凝血因子Ⅱ和Ⅶ以及纤溶酶原水平升高。溴隐亭治疗仅在分娩后6周使凝血因子Ⅸ水平升高。与对照组相比,服用溴隐亭的患者在产褥期催乳素水平较低,促卵泡激素(FSH)水平较高,而服用炔雌醚的患者催乳素水平升高,FSH水平下降较晚。